Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Daltonics Posts Big Revenues, Higher Profits for Q3

NEW YORK, Nov. 5-Bruker Daltonics yesterday posted strong income and powerful revenue growth for the third quarter of 2002


The company reported a net income of $1.7 million or 3 cents per diluted share for the three months ended September 30, 2002. The figure is up sharply from the third quarter of 2001, when Bruker reported net income of $925,000 or 2 cents per diluted share.


Net revenues for the period were $29.7 million, up 25 percent from the $23.8 million that the company posted in the third quarter of 2001. Revenues exceeded consensus estimates.


Bruker's R&D spending was $5.1 million for the quarter, up from $4.8 million in Q3 of 2001.


The company held cash and short-term investments of $49.6 million as of September 30, 2002.


For further details, see the company statement.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.